Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.55 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | CHUK | O15111 | 2/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29751394 | 1.00 | AXL (0.55) | AXLIMPDH2LOXL2IDO1GAA | |
| SCHEMBL3713073 | 0.92 | AXL (0.60) | AXLIMPDH2LOXL2IDO1GAA | |
| SCHEMBL29456309 | 0.92 | AXL (0.60) | AXLIMPDH2LOXL2IDO1GAA | |
| SCHEMBL244397 | 0.84 | AXL (0.72) | AXLIMPDH2IDO1GAAMAPT | |
| SCHEMBL29890100 | 0.84 | AXL (0.72) | AXLIMPDH2IDO1GAAMAPT | |
| SCHEMBL29523064 | 0.76 | AXL (0.43) | AXLIMPDH2LOXL2IDO1GAA | |
| SCHEMBL22787705 | 0.76 | AXL (0.43) | AXLIMPDH2LOXL2IDO1GAA | |
| SCHEMBL27195946 | 0.75 | AXL (0.60) | AXLIMPDH2LOXL2IDO1GAA | |
| SCHEMBL19662991 | 0.75 | TDO2 (0.38) | AXLLOXL2GAAMAPTTDP1 | |
| SCHEMBL24724775 | 0.75 | AXL (0.55) | AXLIMPDH2IDO1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4387963-B1 | PHENYL- AND PYRIDOPYRAZOLE DERIVATIVES AS INHIBITORS OF DDR1 | REDX PHARMA LTD (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-12391695-B2 | PRMT5 inhibitors | LUPIN LIMITED (IN) | 2025-08-19 | — | — | US | disclosed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | disclosed |
| CN-114026094-B | PRMT5 inhibitors | 印度鲁宾有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024079072-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | BIODOL THERAPEUTICS (FR) | 2024-04-18 | — | — | WO | disclosed |
| EP-4353712-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2024-04-17 | — | — | EP | disclosed |
| CN-115232144-B | Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-3980417-B1 | PRMT5 INHIBITORS | LUPIN LTD (IN) | 2023-09-27 | — | — | EP | disclosed |
| EP-3980417-B1 | PRMT5 INHIBITORS | LUPIN LTD (IN) | 2023-09-27 | — | — | EP | disclosed |
| WO-2023165523-A1 | AROMATIC RING-SUBSTITUTED METHOXY DERIVATIVE AND USE THEREOF | 上海璎黎药业有限公司 | 2023-09-07 | — | — | WO | disclosed |
| US-20220315589-A1 | PRMT5 INHIBITORS | LUPIN LIMITED (IN) | 2022-10-06 | — | — | US | disclosed |
| US-20220315589-A1 | PRMT5 INHIBITORS | LUPIN LIMITED (IN) | 2022-10-06 | — | — | US | disclosed |
| CN-115135651-A | Substituted nucleoside analogs as PRMT5 inhibitors | 鲁皮恩有限公司 | 2022-09-30 | — | — | CN | disclosed |
| EP-3596051-B1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD (IN) | 2022-04-27 | — | — | EP | disclosed |
| EP-3980417-A1 | PRMT5 INHIBITORS | Lupin Limited (IN) | 2022-04-13 | — | — | EP | disclosed |
| CN-114026094-A | PRMT5 inhibitor | 印度鲁宾有限公司 | 2022-02-08 | — | — | CN | disclosed |
| WO-2021111322-A1 | SUBSTITUTED NUCLEOSIDE ANALOGS AS PRMT5 INHIBITORS | LUPIN LIMITED (IN) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021111322-A1 | SUBSTITUTED NUCLEOSIDE ANALOGS AS PRMT5 INHIBITORS | LUPIN LIMITED (IN) | 2021-06-10 | — | — | WO | disclosed |
| WO-2020250123-A1 | PRMT5 INHIBITORS | LUPIN LIMITED (IN) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020250123-A1 | PRMT5 INHIBITORS | LUPIN LIMITED (IN) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315589-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | AXL 2715/4885IMPDH2 350/4885LOXL2 3592/4885 |
| US-12391695-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | AXL 2715/4885IMPDH2 350/4885LOXL2 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.